Xigent Bio Secures Bronze Award at the Greater Bay Area Postdoctoral Innovation and Entrepreneurship Competition

Recently, the three-day final of the Second Greater Bay Area Doctoral and Postdoctoral Innovation and Entrepreneurship Competition concluded successfully in Nansha, Guangzhou. This competition is a high-level event held at the provincial level in the Greater Bay Area, attracting the participation of many outstanding projects. After fierce preliminary and semi-final rounds, SIGNET stood out with its strength in "Tumor Innovative Targeted Drug Development Based on Organoids + AI" Project,Emerging from over 200 high-level full-industry final projects, eventuallyWon the Bronze Award (Prize money: 100,000 yuan)。

The total bonus for this competition is as high as 10.2 million yuan, which is three times the total amount of the first competition.The projects awarded the Grand Prize, Gold, Silver, and Bronze will be given priority recommendation to participate in the 3rd China National Postdoctoral Innovation and Entrepreneurship Competition.. This is a provincial-level event held in the Guangdong-Hong Kong-Macao Greater Bay Area, targeting the doctoral and postdoctoral community and platforms.The highest specification, the largest scale, the best incentives, and the widest coverageIn the large-scale competition, SIGNET's winning of the bronze award represents the expert jury's high recognition of the company's R&D strength and project prospects. We will continue to work hard and consistently promote biopharmaceutical innovation.

Signet Therapeutics is the first biotech company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. It was initially founded on the Harvard University campus, established in Shenzhen in 2020, and completed an angel round of financing of nearly 150 million yuan within a year. Signet is not only a phonetic translation of "Signet" but also adheres to the vision of "Hopeful Aspirations, Investigating Things to Gain Knowledge." The company leverages organoid disease models that closely resemble the genomic characteristics of patients, playing a key role in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small molecule compounds, it develops first-in-class innovative targeted drugs. Currently, the company has four drug pipelines, with the lead pipeline SIGX1094 being developed as the world's first targeted drug for diffuse gastric cancer, which has now entered Phase I clinical trials. The company has a 1,200-square-meter R&D facility and a 500-square-meter animal laboratory. Signet Therapeutics' disease model platform not only serves its own drug pipelines but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen BrightGene Bio-Medical Technology and Genuine Biotech, contributing to the birth of more innovative drugs.